| Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults HL Stacey, J Rosen, JT Peterson, A Williams-Diaz, V Gakhar, TM Sterling, ... Human vaccines & immunotherapeutics 15 (3), 530-539, 2019 | 103 | 2019 |
| Checking Fine and Gray subdistribution hazards model with cumulative sums of residuals J Li, TH Scheike, MJ Zhang Lifetime data analysis 21 (2), 197-217, 2015 | 73 | 2015 |
| A dose ranging study of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants. ML Rupp R, Hurley D, Grayson S, Li J, Nolan K, McFetridge RD, Hartzel J ... Hum Vaccin Immunother. 15 (3), 549-559, 2019 | 52 | 2019 |
| A phase II trial of safety, tolerability and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in … HL Platt, D Greenberg, B Tapiero, RA Clifford, NP Klein, DC Hurley, ... The Pediatric Infectious Disease Journal 39 (8), 763-770, 2020 | 50 | 2020 |
| Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults≥ 65 years of age previously vaccinated … JT Peterson, HL Stacey, JE MacNair, J Li, JS Hartzel, TM Sterling, ... Human vaccines & immunotherapeutics 15 (3), 540-548, 2019 | 47 | 2019 |
| Effect of hospital volume on processes of breast cancer care: a National Cancer Data Base study TWF Yen, LE Pezzin, J Li, R Sparapani, PW Laud, AB Nattinger Cancer 123 (6), 957-966, 2017 | 44 | 2017 |
| The proportional odds cumulative incidence model for competing risks F Eriksson, J Li, T Scheike, MJ Zhang Biometrics 71 (3), 687-695, 2015 | 40 | 2015 |
| Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator … H Platt, T Omole, J Cardona, NJ Fraser, RA Mularski, C Andrews, ... The Lancet Infectious Diseases 23 (2), 233-246, 2023 | 38 | 2023 |
| Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged≥ 50 years: a … JY Song, CJ Chang, C Andrews, J Diez-Domingo, M Oh, R Dagan, ... Vaccine 39 (43), 6422-6436, 2021 | 34 | 2021 |
| The interplay between hospital and surgeon factors and the use of sentinel lymph node biopsy for breast cancer TWF Yen, J Li, RA Sparapani, PW Laud, AB Nattinger Medicine 95 (31), e4392, 2016 | 24 | 2016 |
| A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15 … R Lupinacci, R Rupp, O Wittawatmongkol, J Jones, J Quinones, B Ulukol, ... Vaccine 41 (5), 1142-1152, 2023 | 23 | 2023 |
| Socioeconomic disparities in mortality among women with incident breast cancer before and after implementation of Medicare Part D AB Nattinger, EM Wozniak, EL McGinley, J Li, P Laud, LE Pezzin Medical care 55 (5), 463-469, 2017 | 21 | 2017 |
| Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged≥ 50 … R Severance, H Schwartz, R Dagan, L Connor, J Li, A Pedley, J Hartzel, ... Human Vaccines & Immunotherapeutics 18 (1), 1-14, 2022 | 20 | 2022 |
| Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose … F Vanhoutte, W Liu, RT Wiedmann, L Haspeslagh, X Cao, K Boundy, ... EBioMedicine 75, 2022 | 19 | 2022 |
| An algorithm to identify the development of lymphedema after breast cancer treatment TWF Yen, PW Laud, RA Sparapani, J Li, AB Nattinger Journal of Cancer Survivorship 9, 161-171, 2015 | 11 | 2015 |
| Weighted comparison of two cumulative incidence functions with R-CIFsmry package J Li, J Le-Rademacher, MJ Zhang Computer methods and programs in biomedicine 116 (3), 205-214, 2014 | 9 | 2014 |
| Evaluation of immunogenicity and safety of VARIVAX™ New Seed Process (NSP) in children SD Senders, ND Bundick, J Li, C Zecca, FA Helmond Human Vaccines & Immunotherapeutics 14 (2), 442-449, 2018 | 4 | 2018 |
| Inpatient housestaff discontinuity of care and patient adverse events KE Fletcher, S Singh, MM Schapira, V Ratkalkar, AM Visotcky, P Laud, ... The American Journal of Medicine 129 (3), 341-347. e21, 2016 | 3 | 2016 |
| Interobserver Reliability of Magnetic Resonance Imaging Predictors of outcome in cervical spine degenerative conditions JK Grochmal, AM Lozen, AP Klein, LP Mark, J Li, MC Wang World Neurosurgery 117, e215-e220, 2018 | 2 | 2018 |
| Safety, tolerability, and immunogenicity of an adult pneumococcal conjugate vaccine, V116 (STRIDE-3): a randomised, double-blind, active comparator controlled, international … HL Platt, C Bruno, E Buntinx, E Pelayo, D Garcia-Huidobro, ... The Lancet Infectious Diseases, 2024 | 1 | 2024 |
